NCT00196937View on ClinicalTrials.gov

Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18

PHASE3CompletedINTERVENTIONAL
Enrollment

667

Participants

Timeline

Start Date

October 7, 2004

Primary Completion Date

December 15, 2005

Study Completion Date

December 15, 2005

Conditions
Infections, Papillomavirus
Interventions
BIOLOGICAL

Cervarix

Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.

Trial Locations (6)

12200

GSK Investigational Site, Berlin

80799

GSK Investigational Site, Munich

97070

GSK Investigational Site, Würzburg

85-021

GSK Investigational Site, Bydgoszcz

60-533

GSK Investigational Site, Poznan

61-709

GSK Investigational Site, Poznan

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00196937 - Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18 | Biotech Hunter | Biotech Hunter